<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="88256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01956162</url>
  </required_header>
  <id_info>
    <org_study_id>PROT-ORTHO-0913</org_study_id>
    <nct_id>NCT01956162</nct_id>
  </id_info>
  <brief_title>Evaluation of a New Device &quot;Orthèse Diabète&quot; in the Healing of Foot Ulcers in Diabetic Patients</brief_title>
  <acronym>ORTHODIAB</acronym>
  <official_title>Evaluation of a New Customized Removable Device With Rocker Sole for Plantar Off-Loading &quot;Orthèse Diabète&quot; in the Healing of Foot Ulcers in Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteor Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société Francophone du Diabète</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Proteor Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center trial, randomized in 2 parallel groups, open label, with a blinded adjudication
      committee (PROBE methodology), comparing &quot;Orthèse Diabète&quot; with &quot;conventional&quot; removable
      devices in terms of healing of ulcers.

      - Primary objective: Evaluate the efficiency of &quot;Orthèse Diabète&quot; compared to &quot;conventional&quot;
      removable devices, in terms of the proportion of diabetic patients whose principal ulcer
      will heal completely at 3 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Secondary objectives

             1. Proportion of patients whose principal ulcer will heal completely at 1, 2 and 6
                months

             2. Proportion of patients in whom all initial plantar ulcers will heal completely at
                1, 2, 3 and 6 months

             3. Percentage of area decrease of the plantar ulcers at 1, 2, 3 and 6 months

             4. Time to healing of the principal ulcer

             5. Appearance of new ulcers

             6. Requirement for amputation

             7. Incidence of the infectious complications

             8. Adherence of wearing

             9. Patient's satisfaction with the prescribed device

        2. Population

             1. 10 centers/110 patients monitored for a period of 6 months maximum

             2. Experimental Group: &quot;Orthèse Diabète&quot; a plantar off-loading custom-made removable
                device

             3. Control group: &quot;Conventional&quot; removable off-loading systems among the devices
                available in France.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficiency of &quot;Orthèse Diabète&quot; compared to &quot;conventional&quot; removable devices, in terms of the proportion of diabetic patients whose principal ulcer will heal completely.</measure>
    <time_frame>At 3 months</time_frame>
    <description>Evaluated by taking photographs, measuring the ulcer area (using Digital Photo Planimetry DPP and the software Tracer.exe). Full healing defined by the adjudication committee based on the analysis of the photographs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose principal plantar ulcer will be fully healed</measure>
    <time_frame>At 1, 2 and 6 months</time_frame>
    <description>Evaluated by taking photographs, measuring the ulcer area (using Digital Photo Planimetry DPP and the software Tracer.exe). Full healing defined by the adjudication committee based on the analysis of the photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients whose all initial plantar ulcers will be fully healed.</measure>
    <time_frame>At 1, 2, 3 and 6 months</time_frame>
    <description>Evaluated by taking photographs, measuring the ulcer area (using Digital Photo Planimetry DPP and the software Tracer.exe). Full healing defined by the adjudication committee based on the analysis of the photographs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage decrease of the ulcer area</measure>
    <time_frame>At 1, 2, 3 and 6 months</time_frame>
    <description>The area is evaluated by the last measurement undertaken during the trial or prior to a serious event (death, amputation, orthopedic or vascular surgery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to healing of the principal ulcer</measure>
    <time_frame>From the patient's off-loading device delivery visit to the date of healing validated by the adjudication committee</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appearance of new ulcers on the affected foot and/or contralateral</measure>
    <time_frame>6 months</time_frame>
    <description>The following elements will be specified: cause, side, location, severity, treatment used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for amputation</measure>
    <time_frame>6 months</time_frame>
    <description>The following elements will be specified: date, side and level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infectious complications</measure>
    <time_frame>6 months</time_frame>
    <description>This covers cutaneous infections (abscess and lymphangitis, erysipelas, hypodermitis, necrotizing fasciitis, gas gangrene), bone infections (osteitis, arthritis, osteoarthritis) or systemic infections requiring antibiotic therapy (oral or parenteral) or surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observance of the equipment</measure>
    <time_frame>6 months</time_frame>
    <description>Daily wear will be evaluated in the 2 groups through a semi-quantitative questionnaire provided to the patient at every visit. This evaluation will be supplemented with readings of the thermal sensor in the &quot;Orthèse Diabète &quot; group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients satisfaction with the prescribed device</measure>
    <time_frame>At 3 months</time_frame>
    <description>Evaluated with the &quot;QUEST ESAT&quot; questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Foot Ulcers in Diabetic Patients</condition>
  <arm_group>
    <arm_group_label>Group &quot;Orthèse Diabète&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using &quot;Orthèse Diabète&quot;, a new customized removable device with rocker sole for plantar off-loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Using &quot;Conventional&quot; removable off-loading systems among the devices available in France</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Orthèse Diabète</intervention_name>
    <arm_group_label>Group &quot;Orthèse Diabète&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>&quot;Conventional&quot; Device</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 or type 2 diabetic patients diagnosed according to the ADA experts consensus
             [ADA 1997] 33

          -  Over 18 years of age

          -  With a sensory neuropathy (abnormal 10 g monofilament test, i.e. not perceived at
             least 2 times in 1 of the 3 areas explored : pulp of the great toe, 1st and 5th
             metatarsal heads)

          -  Without a severe arteriopathy defined by : ABI &lt; 0,7 and/or TcPO2 &lt; 30 mm Hg and/or
             big toe pressure &lt; 30 mm Hg

          -  with one or more plantar ulcerations with an area &gt; 0,25 cm² or an amputation (toes
             or transmetatarsal) open or sutured

          -  not requiring a contralateral off-loading device

          -  Informed about the study and having given their informed and written consent to
             participate

          -  registered with a social security scheme or with the CMU (beneficiary or entitled
             recipient)

          -  having undergone a medical exam

          -  not included in another protocol throughout the study

        Exclusion Criteria:

          -  Severe skin or osteoarticular infection requiring a parenteral antibiotic therapy or
             surgery

          -  Large ulcer of the ipsilateral leg &gt; 20 cm2 of area

          -  Contralateral above heel amputation

          -  Intercurrent disease prohibiting participation in the protocol

          -  Weight over 130 Kg

          -  Person under tutorship or under curatorship

          -  Loss of functional and/or neuropsychological autonomy

          -  Pregnant or likely to be pregnant woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamel Mohammedi, Diabetologist</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bichat Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kamel Mohammedi, Diabetologist</last_name>
    <phone>+33(0)140257301</phone>
    <email>kamel.mohammedi@bch.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Caroline Hilbert, Project Manager</last_name>
    <phone>+33(0)140897386</phone>
    <email>chilbert@umanis.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Bichat Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75877</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamel Mohammedi, Diabetologist</last_name>
      <phone>+33(0)140257301</phone>
      <email>kamel.mohammedi@bch.aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Caroline Hilbert, Proj Manager</last_name>
      <phone>+33(0)140897386</phone>
      <email>chilbert@umanis.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kamel Mohammedi, Diabetologist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.sfdiabete.org/</url>
  </link>
  <reference>
    <citation>1. Malgrange D. Rev Med Interne. 2008; 29 Suppl 2: S231-7. 2. Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet. 2005; 366(9498): 1725-35. 3. Ramsey SD, Newton K, Blough D, McCulloch DK, Sandhu N, Reiber GE, et al. Incidence, outcomes, and cost of foot ulcers in patients with diabetes. Diabetes Care. 1999; 22(3): 382-7. And others... 4. Muller IS, de Grauw WJ, van Gerwen WH, Bartelink ML, van Den Hoogen HJ, Rutten GE. Foot ulceration and lower limb amputation in type 2 diabetic patients in dutch primary health care. Diabetes Care. 2002; 25(3): 570-4. 5. Detournay B, Cros S, Charbonnel B, Grimaldi A, Liard F, Cogneau J, et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab. 2000; 26(5): 363-9. 6. Detournay B, Raccah D, Cadilhac M, Eschwege E. Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab. 2005; 31(3 Pt 2): 3-18. 7. Malgrange D, Richard JL, Leymarie F. Screening diabetic patients at risk for foot ulceration. A multi-centre hospital-based study in France. Diabetes Metab. 2003; 29(3): 261-8. 8. Apelqvist J, Larsson J, Agardh CD. Long-term prognosis for diabetic patients with foot ulcers. J Intern Med. 1993; 233(6): 485-91. 9. Boulton AJ, Vileikyte L, Ragnarson-Tennvall G, Apelqvist J. The global burden of diabetic foot disease. Lancet. 2005; 366(9498): 1719-24. 10. Moxey PW, Hofman D, Hinchliffe RJ, Jones K, Thompson MM, Holt PJ. Epidemiological study of lower limb amputation in England between 2003 and 2008. Br J Surg. 2010; 97(9): 1348-53. 11. Resnick HE, Carter EA, Sosenko JM, Henly SJ, Fabsitz RR, Ness FK, et al. Incidence of lower-extremity amputation in American Indians: the Strong Heart Study. Diabetes Care. 2004; 27(8): 1885-91. 12. Fosse S, Hartemann-Heurtier A, Jacqueminet S, Ha Van G, Grimaldi A, Fagot-Campagna A. Incidence and characteristics of lower limb amputations in people with diabetes. Diabet Med. 2009; 26(4): 391-6.</citation>
  </reference>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>November 17, 2014</lastchanged_date>
  <firstreceived_date>September 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
